Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

NCT05239910 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Change in development plan

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG: Tenalisib

Sponsor

Rhizen Pharmaceuticals SA